Brief Introduction of Peking University Weiming Bioengineering Group Co., Ltd.

After nearly 20 years of development, Weiming Peking University has done a lot of pioneering and breakthrough work for the development of China's bio-industry, made remarkable achievements, formed three advantages: solid industrial foundation, innovative economic model and unique development ideas, and has developed into the flagship enterprise of modern bio-industry in China and one of the enterprise groups with the most international competitive potential in China. In the history of China's bio-industry, it has created a number of "No.1 in the world" and "No.1 in China": it successfully operated the first genetic engineering drug with independent intellectual property rights in China-recombinant interferon α 1b (Seroxat), and became the first brand in the interferon market in China; Successfully managed the first modern biopharmaceutical enterprise in China-Shenzhen Kexing Biological Products Co., Ltd., and made it the first "National 863 Plan Achievement Industrialization Base" in China; The successful development and production of nerve growth factor, the first inactivated SARS virus vaccine, the first avian influenza vaccine for human use in China and the first influenza A vaccine (Panerlaifu. 1) will trigger the third agricultural revolution. The world's first "bio-economic incubator" has been established, the theoretical system of bio-economy has been established, the bio-economic system and the mode of economic bio-restructuring have been established, and the development ideas of bio-industry suitable for China's national conditions have been preliminarily discussed.